MONUMENT BIOSCIENCES

Company Overview

Monument Biosciences is a next generation Alzheimer's & Related Dementia (ADRD) company focused on reducing **neuroinflammation** and enhancing synaptic function. Our initial programs are anchored in **human patient genetics**, recent discoveries in tau homeostasis and **tau seeding**, and the role of **microglia** in neuroinflammation. We have a robust **translational biomarker program** designed to offer precision medicine opportunities to treat the right patients and follow disease progress in response to therapy. Based in Indianapolis, Monument has exclusive license to a pipeline of novel targets from globally recognized NIH/NIA consortiums TREAT-AD & MODEL-AD. Together they have been awarded over $100M to date to establish a fully integrated ADRD drug discovery program. Our founding team includes leading neuro-focused scientists, clinicians, and entrepreneurs from Eli Lilly, Stark Neuroscience Research Institute, and Luson Bioventures with a proven track record in venture creation & drug development.

Problem or Market Opportunity

Alzheimer's Disease is a progressive neurological disorder that affects memory, thinking, and behavior. Disease progression significantly impacts daily task performance and can eventually lead to total dependence on caregivers. The US has over six (6) million people living with AD and this number is expected to double by 2050. There are many forms of related dementia pathologies that add significantly to this burden. The economic impact of ADRD is substantial, with the cost of care estimated to be over $1 trillion globally. The burden of dementia underscores the urgent need for effective prevention, treatment earlier in the course of disease, and care strategies to mitigate its impact on patients, caregivers, and society**.**

Technical & Competitive Advantage

Eisai and Biogen won the first new approval in Alzheimer's in 20 years with their monoclonal antibody targeting Abeta called lecanemab. Lecanemab showed a reduction in disease progression by 27% over two years of therapy, which is a clinically meaningful advance for patients. However, with significant side effects, the drugs are far from a cure. Our approach to next generation ADRD programs incorporates the learnings from these Abeta agents, and we have potential advantages over all programs currently in development. Our initial programs target toxic **tau seeding** and **microglia-driven neuroinflammation** – now considered the hallmark biologies toward curing these diseases. Monument has exclusive rights through the leading institution in these major NIH-funded programs (Indiana University, top 3 in the world).

Regulatory Strategy & Intellectual Property

Our regulatory strategy employs a custom approach for each program to maximize clinical trial design efficiency. Using Monument's translational biomarker platform, we focus on fluid-based biomarkers of neuroinflammation to assess target engagement in early-stage clinical trials (healthy volunteers). This strategy allows us to move into early proof of concept (POC) trials in genetically driven patient populations of Alzheimer's Disease with an informed dose selection. After achieving POC, we will broaden development into stratified ADRD populations.

Key Milestones

Milestone Description	Objective
Expected Seed Milestones	Establishment of expanded scientific R&D team and supporting infrastructure, completion of Candidate Selection (CS) with start of IND enabling studies for neuroinflammation program 1 (INPP5D, siRNA), and completion of CS for the first tau seeding program Bassoon (BSN, siRNA) and second NI program (PLCG2, small molecule)
Expected Series A Milestones	One-to-two IND candidates from internal pipeline; clinical readiness for one-to-two in-licensed programs; biomarker and clinical strategies detailed for lead programs – this would be a leading position in the field

Capitalization History

Year	Grant or Equity Type	Description	Amount
2016 & 2022	NIH/NIA U54	MODEL-AD 1 ($38M) 2016 & MODEL-AD 2 ($49M) 2022	$87M
2019 & 2024	NIH/NIA U54	TREAT-AD 1 (TREAT-AD 2 in process to match the first program funding)	$~73M
2024	Seed Preferred	Founding Seed Round	$15-$20M

Current Round, Terms, and Use of Proceeds

Incubated by Luson Bioventures since 2022, Monument is initiating a $15-20M founding Seed to advance key programs into clinical-ready development. Luson and Dolby Family Ventures led a pre-seed investment, with Elevate & IU Ventures participation. Luson has founded & launched several new biotech ventures since 2007 and Dolby is a globally recognized life science investor with deep ADRD expertise.

Key Team Members and Advisors

The founding team has deep industry, academia, and biotech drug discovery experience, alongside science founders who are leaders in their fields.

Derek A. Small | CEO and Chairman - Experienced CEO executive with 20+ years in the industry, drug development, and venture capital roles; Founding managing director of Luson Bioventures

Alan Palkowitz, PhD | Director and SAB Co-Chair - President & CEO of Indiana Bioscience Research Institute (IBRI); TREAT-AD Lead PI and Co-Director; with 25+ years leading the discovery chemistry program at Eli Lilly and Company

Timothy Richardson, PhD | Chief Scientific Officer - Scientific Director Molecular Innovation of IBRI; Medicinal Chemistry and Chemical Biology Core Leader at TREAT-AD IUSM-Purdue; with 20+ year of discovery chemistry research from Eli Lilly and Company

Bruce Lamb, PhD | SAB Co-Chair - Executive Director of Stark Neuroscience Research Institute; Professor of Psychiatry, Medical & Molecular Genetics, & Alzheimer's Disease Research, IU School of Medicine; MODEL-AD – Director and TREAT-AD Center – Co-Director

Jeff Dage, PhD | Head of Translational R&D – Head of biomarkers and translation research at Stark Neuroscience Research Institute; TREAT-AD PI; with 20+ years at Eli Lilly and Company as Research Fellow and Group Leader of Translational Research

Monument Biosciences, Inc. | 1210 Waterway Blvd, Suite 2000, Indianapolis, IN 46202
Katherine Moynihan | (540) 969-6355 | katie.moynihan@monument.bio